📖 Published in Endoscopy | ESGE 2025 Technical Review.

We're proud to see EndoZip recognized as part of the international standard in endobariatric innovation, and grateful to Dr. Ivo Boskoski and the ESGE review authors for their role in shaping the field.

EndoZip™ is designed to bring consistency and reproducibility to endoscopic gastroplasty, reducing operator dependence while maintaining procedural efficiency. Its automation and ease of use make it particularly suited for outpatient settings and scalable clinical adoption.

– 13.2% total body weight loss at 12 months. – Over 75% of patients achieved >5% TBWL. – Significant improvements in HbA1c, ALT, and waist circumference.

EndoZip™ was recognized among a select group of globally established technologies for its automated mechanism, single-use design, and strong clinical performance. The publication includes a full procedural description and highlights results from our multicenter study:.

Published by the European Society of Gastrointestinal Endoscopy (Endoscopy, 2025), this review outlines the leading devices and techniques shaping the future of endobariatric care.

It’s official: EndoZip™ has been featured in the 2025 ESGE Technical & Technology Review as one of the key systems shaping the field of endoscopic gastric remodeling (EGR).

The trial builds on our published EU clinical data and aligns with the final stages of our CE mark process in Europe. 📄 For more information, the full press release is attached below.

This milestone marks a meaningful step in our U.S. regulatory and commercial strategy. 𝗘𝗻𝗱𝗼𝗭𝗶𝗽™ is designed to automate and standardize ESG procedures- reducing variability, simplifying adoption, and expanding access to minimally invasive obesity treatment.

The multicenter, randomized controlled study will enroll up to 184 patients across up to 10 U.S. sites, with potential expansion to international centers. All participants will receive an active treatment. Enrollment is expected to begin in Q3 2025 with follow-up through mid-2027.

𝗙𝗗𝗔 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗜𝗗𝗘 𝗦𝘁𝘂𝗱𝘆 𝗳𝗼𝗿 𝗘𝗻𝗱𝗼𝗭𝗶𝗽™!. We’re happy to announce that we’ve received FDA Investigational Device Exemption (IDE) approval to initiate a pivotal U.S. clinical trial evaluating the EndoZip™ system for endoscopic sleeve gastroplasty (ESG).

📄 Featured in Gastrointestinal Endoscopy, Vol. 102, Issue 1 (2025), page 5.

This recognition affirms the growing role of automated ESG as a scalable, outpatient-ready solution in the fight against obesity — and the clinical impact EndoZip™ is already delivering.

Cited in the publication is our first-in-human study, which evaluated EndoZip™ in 45 patients (BMI 30–40 kg/m²), demonstrating:. ✔️ A strong safety profile. ✔️ Clinical success. ✔️ 12-month outcomes comparable to other ESG techniques.

Our EndoZip™ system — the world’s first automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG) — was recognized in the Bariatric and Metabolic Endoscopy category.

We made the Top 10!. Nitinotes is proud to be featured in the 2024 Top 10 Endoscopy Topics in Medical Publishing, selected by the Editorial Board of the American Society for Gastrointestinal Endoscopy (ASGE).

Read the full study and watch the procedure here: .

The inclusion of a video demonstration provides a closer look at how automation enhances procedural consistency, reduces variability, and improves physician usability.

We are pleased to share that our multicenter study, "Automatic endoscopic gastroplasty for the treatment of obesity: results from a prospective multicenter study (with video)," is now available in Gastrointestinal Endoscopy’s Articles in Press.

𝗘𝗻𝗱𝗼𝗭𝗶𝗽™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝘁𝘂𝗱𝘆 𝗡𝗼𝘄 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗶𝗻 𝗚𝗮𝘀𝘁𝗿𝗼𝗶𝗻𝘁𝗲𝘀𝘁𝗶𝗻𝗮𝗹 𝗘𝗻𝗱𝗼𝘀𝗰𝗼𝗽𝘆’𝘀 𝗔𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗶𝗻 𝗣𝗿𝗲𝘀𝘀